HR8083119th CongressWALLET

Allowing Greater Access to Safe and Effective Contraception Act

Sponsored By: Representative Hinson, Ashley [R-IA-2]

Introduced

Summary

Speeds approval of routine oral contraceptives. This bill would create a priority-review pathway for FDA supplemental applications for oral contraceptives intended for routine use, waive the user fee for those supplements, and exclude emergency contraceptives and drugs also approved for induced abortion. It would also preserve stricter FDA requirements under section 503(b)(1) for individuals under age 18 even after approval.

Show full summary
  • Families and patients: Could get faster access to more routine birth-control pills. Products for people under age 18 would remain subject to existing FDA restrictions.
  • Drug sponsors and developers: Would get priority review and a waived fee for qualifying supplemental applications. The pathway applies to supplements already pending and those filed after enactment.
  • Federal oversight: Requires the Government Accountability Office to report within one year on 15 years of federal funding for contraception across eight programs, including Medicare, Medicaid, Title X, and TRICARE.

Your PRIA Score

Score Hidden

Personalized for You

How does this bill affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Bill Overview

Analyzed Economic Effects

2 provisions identified: 1 benefits, 0 costs, 1 mixed.

Faster access to birth control for adults

If enacted, the bill would require the Secretary of Health and Human Services to give priority FDA review to supplemental applications for routine oral contraceptive drugs. The priority pathway would exclude emergency contraceptives and drugs also approved for induced abortion. For supplemental applications that get priority review, the FDA fee under 21 U.S.C. 379h(a)(1) would be waived. If the FDA approves removing the prescription rule for people age 18 and older, those people would no longer be subject to that prescription requirement, but people under 18 would still need a prescription. These rules would apply to pending supplemental applications and to ones submitted after enactment.

Study of federal contraception spending

If enacted, the bill would require the Government Accountability Office to study federal funding for contraception over the 15 years before enactment. The study would cover funds for reimbursement, inventory stocking, provider training, and patient education. The GAO would analyze eight programs, including Medicare, Medicaid, Indian Health Service, health insurance exchanges, community health centers, Title X, Temporary Assistance for Needy Families, and TRICARE. The GAO would have to send the report to Congress within one year after enactment.

Sponsors & CoSponsors

Sponsor

Hinson, Ashley [R-IA-2]

IA • R

Cosponsors

  • Rep. Miller-Meeks, Mariannette [R-IA-1]

    IA • R

    Sponsored 3/25/2026

  • Rep. Nunn, Zachary [R-IA-3]

    IA • R

    Sponsored 3/25/2026

  • Ciscomani

    AZ • R

    Sponsored 3/25/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation